ArticleHealthcare policy = Politiques de sante2017
Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison.
Article in Healthcare policy = Politiques de sante, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03862911 (Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Lifetime direct healthcare costs of treating colorectal cancer: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Pooled it
- Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework.Applied health economics and health policy · 2025Article
- Insights from GoFundMe posts: Analyzing GoFundMe financial aid requests from brain tumor patients in Ontario, Canada.Neuro-oncology practice · 2025Article
- Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada.JAMA network open · 2024Article
- Article
- Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada.PharmacoEconomics - open · 2023Article
- Associations between clinical pathway concordance, cost, and survival outcomes for stage II colon cancer: a population-based study.International journal for quality in health care : journal of the International Society for Quality in Health Care · 2023Article
- Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study.Current oncology (Toronto, Ont.) · 2023Article
- Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.Current oncology (Toronto, Ont.) · 2023Article
- Article
- Regional variation in cost of neonatal intensive care for extremely preterm infants.BMC pediatrics · 2021Article
- Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma.Immunotherapy · 2021Article
- The cost of failed first-line cancer treatment related to continued smoking in Canada.Current oncology (Toronto, Ont.) · 2020Article
- Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Article
- Comparing Childhood Cancer Care Costs in Two Canadian Provinces.Healthcare policy = Politiques de sante · 2020Article
- Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada.JCO oncology practice · 2020Article
- The generation of two specific cancer costing algorithms using Ontario administrative databases.Current oncology (Toronto, Ont.) · 2019Article
- A population-level comparison of cancer-related and non-cancer-related health care costs using publicly available provincial administrative data.Current oncology (Toronto, Ont.) · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCosting studies are useful to measure the economic burden of cancer. Comparing costs between healthcare systems can inform evaluation, development or modification of cancer care policies.
objectivesTo estimate and compare cancer costs in British Columbia and Ontario from the payers' perspectives.
methodsUsing linked cancer registry and administrative data, and standardized costing methodology and analyses, we estimated costs for 21 cancer sites by phase of care to determine potential differences between provinces.
resultsOverall, costs were higher in Ontario. Costs were highest in the initial post-diagnosis and pre-death phases and lowest in the pre-diagnosis and continuing phases, and generally higher for brain cancer and multiple myeloma, and lower for melanoma. Hospitalization was the major cost category. Costs for physician services and diagnostic tests differed the most between provinces.
conclusionsThe standardization of data and costing methodology is challenging, but it enables interprovincial and international comparative costing analyses.
Indexed as
Identifiers
28277207PMC5344366W2592529563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.